ArticleFrontiers in genome editing2021
The Application of CRISPR/Cas Systems for Antiviral Therapy.
Article in Frontiers in genome editing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Microneedle patch technologies in virology: bridging immunization, antiviral therapy, and point-of-care diagnostics.Clinical and experimental vaccine research · 2026Review
- Viral genome editing methods and applications in the CRISPR era.Journal of virology · 2026Review
- The application of CRISPR gene-editing technology in influenza prevention and control.Frontiers in genome editing · 2026Review
- CRISPR/Cas genome editing, functional genomics, and diagnostics for parasitic helminths.International journal for parasitology · 2025Review
- CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential.Cell proliferation · 2025Article
- Lung virome convergence precedes hospital-acquired pneumonia in intubated critically ill patients.Cell reports. Medicine · 2025Article
- Applying CRISPR Technologies for the Treatment of Human Herpesvirus Infections: A Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- Tissue nanotransfection and cellular reprogramming in regenerative medicine and antimicrobial dynamics.Frontiers in bioengineering and biotechnology · 2025Review
- Review
- Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.Vaccines · 2024Review
- Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins.Scientific reports · 2023Article
- Delivery of siRNAs against MERS-CoV in Vero and HEK-293 cells: A comparative evaluation of transfection reagents.Journal of King Saud University. Science · 2023Article
- Computational Design and Experimental Evaluation of MERS-CoV siRNAs in Selected Cell Lines.Diagnostics (Basel, Switzerland) · 2023Article
- The convergent evolution of influenza A virus: Implications, therapeutic strategies and what we need to know.Current research in microbial sciences · 2023Article
- Seven classes of antiviral agents.Cellular and molecular life sciences : CMLS · 2022Review
- XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection.Nature communications · 2022Article
- Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.Nature chemical biology · 2022Article
- CRISPR-Cas system: from diagnostic tool to potential antiviral treatment.Applied microbiology and biotechnology · 2022Review
- A Novel Approach of Antiviral Drugs Targeting Viral Genomes.Microorganisms · 2022Review
- Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics.Bioengineering (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As CRISPR/Cas systems have been refined over time, there has been an effort to apply them to real world problems, such as developing sequence-targeted antiviral therapies. Viruses pose a major threat to humans and new tools are urgently needed to combat these rapidly mutating pathogens. Importantly, a variety of CRISPR systems have the potential to directly cleave DNA and RNA viral genomes, in a targeted and easily-adaptable manner, thus preventing or treating infections. This perspective article highlights recent studies using different Cas effectors against various RNA viruses causing acute infections in humans; a latent virus (HIV-1); a chronic virus (hepatitis B); and viruses infecting livestock and animal species of industrial importance. The outlook and remaining challenges are discussed, particularly in the context of tacking newly emerging viruses, such as SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.